<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04290572</url>
  </required_header>
  <id_info>
    <org_study_id>176/2019</org_study_id>
    <nct_id>NCT04290572</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Oral Isotretinoin for the Treatment of Facial Recalcitrant Flat Warts</brief_title>
  <official_title>Efficacy and Safety of Oral Isotretinoin 10 mg, 20 mg and 30 mg for the Treatment of Facial Recalcitrant Flat Warts at Centro Dermatológico &quot;Dr. Ladislao de la Pascua&quot;: Randomized Double-blinded Clinical Trial of Three Arms</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centro Dermatológico Dr. Ladislao de la Pascua</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centro Dermatológico Dr. Ladislao de la Pascua</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Randomized clinical trial to compare the efficacy of different doses of oral isotretinoin 10
      mg/day, 20 mg/day and 30 mg/day during 12 weeks for the treatment of facial recalcitrant flat
      warts. The primary endpoint will be the proportion of participants with total remission of
      facial flat warts at the end of the intervention in the three arms of the clinical trial.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators will recruit 162 participants with facial recalcitrant flat warts and
      randomize to the following three arms of intervention: Arm 1: nne capsule of isotretinoin 10
      mg plus one capsule of placebo, per day during 12 weeks; Arm 2: one capsule of isotretinoin
      20 mg plus one capsule of placebo, per day during 12 weeks; and Arm 3: one capsule of
      isotretinoin 10 mg plus one capsule of isotretinoin 20 mg, per day during 12 weeks. The
      primary endpoints will be the proportion of participants with total remission of facial flat
      warts at the end of the intervention in the three arms of the clinical trial; and the
      incidence of side effects related to oral isotretinoin treatment among the 3 arms of
      treatment.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 15, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">February 28, 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized clinical trial of three-arms</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
    <masking_description>All the interventions will be similar in appearance and all the participants will take the same quantity of capsules.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Complete clearance</measure>
    <time_frame>12 weeks</time_frame>
    <description>Proportion of participants with total remission of facial flat warts at the end of the intervention in the three arms of the clinical trial.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of serious adverse events</measure>
    <time_frame>12 weeks</time_frame>
    <description>Proportion of participants that developed a serious side effect in the three arms during the clinical trial.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of life index</measure>
    <time_frame>12 weeks</time_frame>
    <description>Difference in the Dermatology Life Quality Index score at the end of the study, comparing with the basal score. The minimum score is 0 points and the maximum 30 points. A score higher than 10 points means that the patient's life is severely affected by melasma.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adherence to intervention</measure>
    <time_frame>12 weeks</time_frame>
    <description>Percentage of taken-doses of oral isotretinoin during the 12 weeks of the study.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">162</enrollment>
  <condition>Flat Wart</condition>
  <arm_group>
    <arm_group_label>Isotretinoin 10 mg/day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One capsule of isotretinoin 10 mg plus one capsule of placebo, per day during 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Isotretinoin 20 mg/day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>One capsule of isotretinoin 20 mg plus one capsule of placebo, per day during 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Isotretinoin 30 mg/day</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>One capsule of isotretinoin 10 mg plus one capsule of isotretinoin 20 mg, per day during 12 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Isotretinoin capsules</intervention_name>
    <description>Jelly capsules of isotretinoin</description>
    <arm_group_label>Isotretinoin 10 mg/day</arm_group_label>
    <arm_group_label>Isotretinoin 20 mg/day</arm_group_label>
    <arm_group_label>Isotretinoin 30 mg/day</arm_group_label>
    <other_name>Oral retinoid</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical and histological diagnosis of facial flats warts

          -  More than 2 years with facial flat warts

          -  Without response to 2 or more topical interventions (tretinoin, imiquimod, cryosurgery
             and 5-fluorouracil) or oral interventions (cimetidine or zinc sulfate)

        Exclusion Criteria:

          -  Have the following conditions:

               1. Hypercholesterolemia

               2. Hypertriglyceridemia

               3. Liver disease

               4. Renal disease

               5. Sjögren syndrome

               6. Pregnancy

               7. Lactation

               8. Depressive disorder

               9. Body mass index less than 18 points or higher than 25 points

              10. Contraindications for hormonal contraception or intrauterine device.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>María Guadalupe Olguín-García, M.D.,MSc.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centro Dermatológico Dr. Ladislao de la Pascua</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>María Guadalupe Olguín-García, M.D., MSc.</last_name>
    <phone>55387033</phone>
    <phone_ext>312</phone_ext>
    <email>olguingog@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Martha Alejandra Morales-Sánchez, M.D., MSc.</last_name>
    <phone>55387033</phone>
    <phone_ext>312</phone_ext>
    <email>mmoraless@sersalud.cdmx.gob.mx</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centro Dermatológico &quot;Dr. Ladislao de la Pascua&quot;</name>
      <address>
        <city>Mexico City</city>
        <zip>06780</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Mexico</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>February 27, 2020</study_first_submitted>
  <study_first_submitted_qc>February 28, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 2, 2020</study_first_posted>
  <last_update_submitted>February 28, 2020</last_update_submitted>
  <last_update_submitted_qc>February 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>flat wart</keyword>
  <keyword>isotretinoin</keyword>
  <keyword>facial warts</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Warts</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Isotretinoin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

